Athira Pharma. has been granted a patent for a method to treat Parkinson’s Disease and Lewy body disorders by administering ATH-1017. The treatment involves dosages of 40 or 70 mg per day for patients in need. GlobalData’s report on Athira Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athira Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Athira Pharma's grant share as of June 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (US11998556B2) outlines a method for treating Parkinson's disease (PD) and Lewy body disease (LBD) through the administration of a compound referred to as formula A19. The treatment involves administering either 40 mg or 70 mg of this compound daily to patients diagnosed with PD, LBD, or Parkinson's disease dementia (PDD). The claims specify that the method is applicable to patients aged between 40 and 85 years and those at Hoehn-Yahr stages 1 to 4, indicating a focus on various stages of these neurodegenerative disorders.
The patent further details the potential benefits of the treatment, including improvements in motor symptoms and cognitive functions, as measured by various scales such as the Alzheimer's Disease Assessment Scale—cognitive subscale (ADAS-Cog13) and the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Additionally, the method aims to slow the decline in daily living activities and verbal fluency, with effects observable from as early as two weeks to up to 26 weeks after treatment initiation. The administration route specified is subcutaneous injection, and the claims also include the use of a monosodium salt form of the compound. Overall, the patent presents a comprehensive approach to managing symptoms associated with PD and LBD, emphasizing both motor and cognitive improvements.
To know more about GlobalData’s detailed insights on Athira Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
